Medically reviewed by Ritchie Stevens, MD, Radiation Oncologist on June 8, 2026.
_1782506263683-DvIGI5Jo.jpg)
Adaptive radiotherapy for lung cancer
Lung tumors move with every breath — often shifting a centimeter or more within a single session. Conventional radiation treats a large volume to account for this motion, damaging healthy lung tissue in the process. Adaptive SBRT on the Akesis Gemini 360 tracks the tumor's actual position and adapts the plan before each beam delivery, protecting the lung tissue the patient needs.
Why Lung Cancer needs more than a fixed plan
Lung cancer presents some of the most complex challenges in radiation therapy. These three factors explain why conventional approaches fall short of what adaptive radiotherapy can achieve.
Respiratory motion
Lung tumors move 5–30 mm with each breath cycle, depending on tumor location. Conventional machines treat a large internal target volume that encompasses all possible tumor positions — irradiating healthy lung tissue throughout.
Tumor volume changes
Lung tumors often shrink during a multi-week course of radiation. A fixed plan built on the original tumor size continues to treat tissue that no longer contains active cancer, unnecessarily exposing adjacent structures.
Adjacent critical structures
The esophagus, heart, spinal cord, and major airways lie close to most lung tumors. Wide margins used to compensate for motion uncertainty increase dose to these structures, raising the risk of esophagitis, cardiac toxicity, and radiation pneumonitis.
What the evidence shows
Lung SBRT has one of the most robust evidence bases in radiation oncology, with multiple trials demonstrating cure rates approaching surgery for early-stage disease.
RTOG 0236: 97.6% local control at 3 years
This landmark NCI-sponsored trial treated inoperable stage I non-small cell lung cancer patients with 3-fraction SBRT. At 3 years, primary tumor control was 97.6% — establishing SBRT as the standard of care for medically inoperable early-stage lung cancer.
doi.org/10.1001/jama.2010.261STARS/ROSEL: SBRT equals surgery for operable patients
A pooled analysis of two randomized trials comparing SBRT to lobectomy in operable stage I NSCLC found comparable 3-year overall survival (95% vs. 79%) and local recurrence rates. SBRT patients had significantly fewer severe adverse events, suggesting SBRT as a valid surgical alternative for selected patients.
doi.org/10.1016/S1470-2045(15)70168-3SABR-COMET: improved survival with oligometastatic lung SBRT
This randomized phase 2 trial found that adding SBRT to standard of care for patients with oligometastatic disease (including lung metastases) improved overall survival at 5 years (42.3% vs. 17.7%) — supporting the role of precise ablative RT in metastatic lung disease.
doi.org/10.1200/JCO.20.00818Your treatment workflow
At 5D Cancer Services, lung SBRT follows a rigorous protocol designed to account for respiratory motion at every step — from planning to treatment delivery.
4D CT simulation
A four-dimensional CT captures the tumor through the full breathing cycle, creating a motion envelope. This data informs the internal target volume (ITV) and shapes the adaptive replanning that happens at every treatment session.
Treatment planning
The radiation oncologist contours the tumor, motion envelope, and all adjacent critical structures — esophagus, heart, spinal cord, and uninvolved lung. The plan is optimized to deliver ablative dose to the ITV while staying within published organ-at-risk constraints.
Daily CBCT imaging and adaptation (sessions 1–5)
Before each treatment, a CBCT is acquired. The Gemini 360 identifies the tumor's position in today's anatomy, adapts the delivery accordingly, and confirms the plan before the beam is turned on. Each session is approximately 30–60 minutes.
Follow-up CT at 3, 6, and 12 months
Imaging follow-up tracks tumor response and monitors for late toxicity (pneumonitis, fibrosis). Most patients who achieve local control at 12 months maintain durable disease-free status.
Adaptive vs. conventional radiation
| Factor | Adaptive RT (Gemini 360) | Conventional Radiation |
|---|---|---|
| Total sessions | 3–5 (early stage) or 15–30 (advanced) | 30–33 sessions over 6–7 weeks |
| Daily imaging | CBCT at every session | Periodic kV imaging or none |
| Respiratory management | Daily adaptation to actual position | Large ITV to encompass motion |
| Healthy lung volume irradiated | Significantly reduced | Larger volume due to motion margins |
| Local control (early stage) | ~97% at 3 years (RTOG 0236) | ~80–90% with IMRT |
| Pneumonitis risk | Reduced — precise margins | Higher with larger fields |
Frequently asked questions
Can SBRT cure early-stage lung cancer?
Yes. For patients with stage I non-small cell lung cancer who are not surgical candidates — or who prefer to avoid surgery — SBRT achieves cure rates comparable to lobectomy, with published local control rates above 90–97% at 3 years. Your radiation oncologist will review your staging CT and PET to confirm whether SBRT is appropriate.
What is radiation pneumonitis and how is it prevented?
Radiation pneumonitis is inflammation of the lung caused by radiation exposure to healthy tissue. The Gemini 360 reduces this risk by tracking the tumor's actual position and adapting each session's plan, so the volume of healthy lung receiving high dose is minimized. Most patients who do develop mild pneumonitis respond to short-course corticosteroids.
How does adaptive SBRT handle breathing motion?
The planning process captures the tumor's full range of motion through the breathing cycle using a 4D CT. At each treatment session, a CBCT is acquired and the plan is adapted to account for where the tumor is on that day. This eliminates the large motion-compensation margins used in conventional lung radiation, protecting healthy tissue adjacent to the tumor.
Can lung metastases from other cancers be treated?
Yes. Adaptive SBRT is highly effective for oligometastatic lung disease — one to five lung metastases from another primary cancer. The Gemini 360 can target individual lesions with high precision. The SABR-COMET trial demonstrated a survival benefit when SBRT is added to systemic therapy for oligometastatic patients.
Educational information — not medical advice
The content on this page is provided for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this site. If you think you may have a medical emergency, call your doctor or 911 immediately.
References
- 1.Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076. doi.org/10.1001/jama.2010.261
- 2.Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–637. doi.org/10.1016/S1470-2045(15)70168-3
- 3.Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38(25):2830–2838. doi.org/10.1200/JCO.20.00818
Also see: Adaptive RT by cancer type
Please do not send Protected Health Information (PHI) by email or voicemail. Standard email is not secure — call us and we will arrange a secure channel.
